This site is intended for healthcare professionals
Improving treatment options for childhood psoriasis
Declaration of sponsorship Novartis Pharma AG


Declaration of sponsorship Novartis Pharma AG
Read time: 270 mins
Last updated:18th Oct 2021
Published:4th Jul 2020
Are you doing enough for your paediatric patients with moderate-to-severe psoriasis? The burden of psoriasis is greatest for our youngest patients, like Mia, but current treatment options are limited. Find out how that is set to change. h

This Learning Zone introduces you to our young patient Mia who along with our paediatric psoriasis experts , helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options. 

Mia’s treatment history helps us describe the current treatments available and we also look to the future for Mia using a summary of the clinical trials of more targeted treatments underway.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest


  1. World Health Organization. Psoriasis. 2016. Available at: Accessed 27 April 2020.
  2. Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, et al. Prevalence of psoriasis in children and adolescents in the United States: A claims-based analysis. J Drugs Dermatology. 2018;17(2):187–194.
  3. Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). Available at: Accessed 13 January 2021.
  4. Cosentyx 150 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) Avai. Accessed 13 January 2021.